Autologous haematopoietic-stem-cell transplantation for multiple sclerosis

Lancet Neurology

Volumn 4, Issue 1, 2005, Pages 54-63

  Blanco, Yolanda ^a   Saiz, Albert ^a,c   Carreras, Enric ^b   Graus, Francesc ^a  

^a Hospital Clinic   (Spain)

^b Hospital Clinico   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; MITOXANTRONE; PREDNISONE; THYMOCYTE ANTIBODY;

ALLERGIC ENCEPHALOMYELITIS; AUTOTRANSPLANTATION; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; FEVER; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INFUSION; META ANALYSIS; MULTIPLE SCLEROSIS; NERVOUS SYSTEM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; WHOLE BODY RADIATION;

CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 11144305796     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(04)00966-4     Document Type: Review

References (69)

1. Compston A, Coles A. Multiple sclerosis. Lancet. 359:2002;1221-1231
2. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 343:2000;938-952
3. O'Connor P. Key issues in the diagnosis and treatment of multiple sclerosis: an overview. Neurology. 59:2002;S1-33
4. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 360:2002;2018-2025
5. Armitage JO. Bone marrow transplantation. N Engl J Med. 330:1994;827-838
6. Morton JI, Siegel BV. Transplantation of autoimmune potential, I: development of antinuclear antibodies in H-2 histocompatible recipients of bone marrow from New Zealand Black mice. Proc Natl Acad Sci USA. 71:1974;2162-2165
7. van Bekkum DW. Experimental basis of hematopoietic stem cell transplantation for treatment of autoimmune diseases. J Leukoc Biol. 72:2002;609-620
8. Marmont AM. Immune ablation followed by allogeneic or autologous bone marrow transplantation: a new treatment for severe autoimmune diseases? Stem Cells. 12:1994;125-135
9. Ikehara S. Bone marrow transplantation for autoimmune diseases. Acta Haematol. 99:1998;116-132
10. Nelson JL, Torrez R, Louie FM, Choe OS, Storb R, Sullivan KM. Pre-existing autoimmune disease in patients with long-term survival after allogeneic bone marrow transplantation. J Rheumatol Suppl. 48:1997;23-29
11. Mandalfino P, Rice G, Smith A, Klein JL, Rystedt L, Ebers GC. Bone marrow transplantation in multiple sclerosis. J Neurol. 247:2000;691-695
12. Lee WY, Oh ES, Min CK, et al. Changes in autoimmune thyroid disease following allogeneic bone marrow transplantation. Bone Marrow Transplant. 28:2001;63-66
13. van Gelder M, van Bekkum DW. Treatment of relapsing experimental autoimmune encephalomyelitis in rats with allogeneic bone marrow transplantation from a resistant strain. Bone Marrow Transplant. 16:1995;343-351
14. van Gelder M, Mulder AH, van Bekkum DW. Treatment of relapsing experimental autoimmune encephalomyelitis with largely MHC-matched allogeneic bone marrow transplantation. Transplantation. 62:1996;810-818
15. van Gelder M, van Bekkum DW. Effective treatment of relapsing experimental autoimmune encephalomyelitis with pseudoautologous bone marrow transplantation. Bone Marrow Transplant. 18:1996;1029-1034
16. Tyndall A, Gratwohl A. Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 19:1997;643-645
17. Fassas A, Passweg JR, Anagnostopoulos A, et al. Hematopoietic stem cell transplantation for multiple sclerosis: a retrospective multicenter study. J Neurol. 249:2002;1088-1097
18. Comi G, Kappos L, Clanet M, et al. Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation. J Neurol. 247:2000;376-382
19. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 344:2001;175-181
20. Openshaw H, Stuve O, Antel JP, et al. Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology. 54:2000;2147-2150
21. Snowden JA, Biggs JC, Milliken ST, et al. A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis. Bone Marrow Transplant. 22:1998;1035-1041
22. Euler HH, Harten P, Zeuner RA, Schwab UM. Recombinant human granulocyte colony stimulating factor in patients with systemic lupus erythematosus associated neutropenia and refractory infections. J Rheumatol. 24:1997;2153-2157
23. Openshaw H, Nash RA, McSweeney PA. High-dose immunosuppression and hematopoietic stem cell transplantation in autoimmune disease: clinical review. Biol Blood Marrow Transplant. 8:2002;233-248
24. Euler HH, Marmont AM, Bacigalupo A, et al. Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. Blood. 88:1996;3621-3625
25. van Bekkum DW. Autologous stem cell transplantation for treatment of autoimmune diseases. Stem Cells. 17:1999;172-178
26. van Bekkum DW, Balner H, Dicke KA, van den Berg FG, Prinsen GH, Hollander CF. The effect of pretreatment of allogeneic bone marrow graft recipients with antilymphocytic serum on the acute graft-versus-host reaction in monkeys. Transplantation. 13:1972;400-407
27. Vogel W, Scheding S, Kanz L, Brugger W. Clinical applications of CD34(+) peripheral blood progenitor cells (PBPC). Stem Cells. 18:2000;87-92
28. Bomberger C, Singh-Jairam M, Rodey G, et al. Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors. Blood. 91:1998;2588-2600
29. Martinez C, Urbano-Ispizua A, Rozman C, et al. Immune reconstitution following allogeneic peripheral blood progenitor cell transplantation: comparison of recipients of positive CD34+ selected grafts with recipients of unmanipulated grafts. Exp Hematol. 27:1999;561-568
30. Rutella S, Rumi C, Laurenti L, et al. Immune reconstitution after transplantation of autologous peripheral CD34+ cells: analysis of predictive factors and comparison with unselected progenitor transplants. Br J Haematol. 108:2000;105-115
31. Baron F, Schaaf-Lafontaine N, Humblet-Baron S, et al. T-cell reconstitution after unmanipulated, CD8-depleted or CD34-selected nonmyeloablative peripheral blood stem-cell transplantation. Transplantation. 76:2003;1705-1713
32. Sica S, Salutari P, La Barbera EO, Sora F, Piccirillo N, Leone G. Infectious complications after CD34-selected autologous peripheral blood stem cell transplantation. Br J Haematol. 101:1998;592-593
33. Holmberg LA, Boeckh M, Hooper H, et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood. 94:1999;4029-4035
34. Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant. 31:2003;145-155
35. Moore J, Brooks P, Milliken S, et al. A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Arthritis Rheum. 46:2002;2301-2309
36. Knaan-Shanzer S, Houben P, Kinwel-Bohre EP, van Bekkum DW. Remission induction of adjuvant arthritis in rats by total body irradiation and autologous bone marrow transplantation. Bone Marrow Transplant. 8:1991;333-338
37. Fassas A, Anagnostopoulos A, Kazis A, et al. Autologous stem cell transplantation in progressive multiple sclerosis - an interim analysis of efficacy. J Clin Immunol. 20:2000;24-30
38. Fassas A, Kimiskidis VK. Stem cell transplantation for multiple sclerosis: what is the evidence? Blood Rev. 17:2003;233-240
39. Kozak T, Havrdova E, Pit'ha J, et al. High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transplant. 25:2000;525-531
40. Kozak T, Havrdova E, Pit'ha J, et al. Immunoablative therapy with autologous stem cell transplantation in the treatment of poor risk multiple sclerosis. Transplant Proc. 33:2001;2179-2181
41. Mancardi GL, Saccardi R, Filippi M, et al. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology. 57:2001;62-68
42. Nash RA, Bowen JD, McSweeney PA, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood. 102:2003;2364-2372
43. Burt RK, Cohen BA, Russell E, et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood. 102:2003;2373-2378
44. Carreras E, Saiz A, Marin P, et al. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. Haematologica. 88:2003;306-314
45. Saiz A, Blanco Y, Carreras E, et al. Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS. Neurology. 62:2004;282-284
46. Openshaw H, Lund BT, Kashyap A, et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplant. 6:2000;563-575
47. Karussis DM, Slavin S, Lehmann D, Mizrachi-Koll R, Abramsky O, Ben-Nun A. Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation. J Immunol. 148:1992;1693-1698
48. van Gelder M, Kinwel-Bohre EP, van Bekkum DW. Treatment of experimental allergic encephalomyelitis in rats with total body irradiation and syngeneic BMT. Bone Marrow Transplant. 11:1993;233-241
49. Peterson K, Rosenblum MK, Powers JM, Alvord E, Walker RW, Posner JB. Effect of brain irradiation on demyelinating lesions. Neurology. 43:1993;2105-2112
50. Friedman DP, Morales RE, Goldman HW. Role of enhanced MRI in the follow-up of patients with medically refractory trigeminal neuralgia undergoing stereotactic radiosurgery using the gamma knife: initial experience. J Comput Assist Tomogr. 25:2001;727-732
51. Murphy CB, Hashimoto SA, Graeb D, Thiessen BA. Clinical exacerbation of multiple sclerosis following radiotherapy. Arch Neurol. 60:2003;273-275
52. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 36:1997;897-904
53. The European Group for Blood and Marrow Transplantation. Autoimmune Disease Working Party: ongoing studies. http://www.ebmt.org (accessed Dec 1, 2004)
54. Bronnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain. 127:2004;844-850
55. Oyama Y, Cohen B, Traynor A, Brush M, Rodriguez J, Burt RK. Engraftment syndrome: a common cause for rash and fever following autologous hematopoietic stem cell transplantation for multiple sclerosis. Bone Marrow Transplant. 29:2002;81-85
56. Sanmarco M, Vialettes B, Maraninchi D, Bernard D. Autoantibody formation after bone marrow transplantation: a comparison between autologous and allogeneic grafts. Autoimmunity. 11:1991;7-12
57. Lambertenghi Deliliers G, Annaloro C, Lambertenghi Deliliers D. Complications of autologous hematopoietic stem cell transplantation. Haematologia. 30:2000;253-262
58. Inglese M, Mancardi GL, Pagani E, et al. Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. J Neurol Neurosurg Psychiatry. 75:2004;643-644
59. O'Connor P. Key issues in the diagnosis and treatment of multiple sclerosis: an overview. Neurology. 59:2002;S1-33
60. Simon JH, Jacobs LD, Campion MK, et al. A longitudinal study of brain atrophy in relapsing multiple sclerosis. Neurology. 53:1999;139-148
61. Paolillo A, Pozzilli C, Giugni E, et al. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta. Eur J Neurol. 9:2002;645-655
62. Rovaris M, Comi G, Rocca MA, Wolinsky JS, Filippi M. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain. 124:2001;1803-1812
63. Jager HR, Williams EJ, Savage DG, et al. Assessment of brain changes with registered MR before and after bone marrow transplantation for chronic myeloid leukemia. AJNR Am J Neuroradiol. 17:1996;1275-1282
64. Saiz A, Carreras E, Berenguer J, et al. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS. Neurology. 56:2001;1084-1089
65. Mitus AJ, Stein R, Rappeport JM, et al. Monoclonal and oligoclonal gammopathy after bone marrow transplantation. Blood. 74:1989;2764-2768
66. Burt RK, Traynor AE, Pope R, et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood. 92:1998;3505-3514
67. Porrata LF, Litzow MR, Markovic SN. Immune reconstitution after autologous hematopoietic stem cell transplantation. Mayo Clin Proc. 76:2001;407-412
68. Reimer P, Kunzmann V, Wilhelm M, et al. Cellular and humoral immune reconstitution after autologous peripheral blood stem cell transplantation (PBSCT). Ann Hematol. 82:2003;263-270
69. Sun W, Popat U, Hutton G, et al. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain. 127:2004;996-1008